REMEGEN (09995) released its annual performance, with a net profit attributable to shareholders of 710 million yuan, turning losses into profits year-on-year.

REMEGEN (09995) announced its annual performance as of December 31, 2025. The group generated revenue of 3.242 billion yuan (unit same below), an increase of 89.55% year-on-year; the attributable profit to the owners of the parent company was 710 million yuan, compared to a loss of 1.468 billion yuan in the same period last year; earnings per share were 1.29 yuan. The group's product sales revenue for the fiscal year ending December 31, 2025 was approximately 2.307 billion yuan, an increase of 35.8% from 1.699 billion yuan in the same period last year, mainly driven by strong sales growth of the company's own commercialized products: RC18 (trade name: Tai Ai) in the immunotherapy category and RC48 (trade name: Ai Di Xi) in the anti-tumor category. As the world's first innovative dual-target biological agent for SLE treatment, Tai Ai has been approved for market listing by the Chinese National Medical Products Administration in March 2021. In December of the same year, the product was included in the National Medical Insurance Drug List for the treatment of SLE, and successfully renewed in 2023 and 2025. In December 2025, the product was included in the National Medical Insurance Drug List for the treatment of gMG. As of December 31, 2025, Tai Ai has been approved in over 1,200 hospitals. Wei Di Xi Tuo monoclonal antibody was approved for market listing by the Chinese National Medical Products Administration in June 2021 and sales began in July of the same year. At the end of 2021, the indications for the treatment of HER2-positive advanced gastric cancer (GC) were included in the new version of the National Medical Insurance Drug List. In January 2023, the indications for the treatment of HER2-positive urothelial carcinoma (UC) were included in the National Medical Insurance Drug List. Both indications for this product were successfully renewed by the end of 2025. As of December 31, 2025, Wei Di Xi Tuo monoclonal antibody has been approved in over 1,050 hospitals. With the professional knowledge and industry connections of the company team, as well as the significant increase in accessibility after the inclusion of two core products in the National Medical Insurance Drug List, the company mainly promotes its products through further marketing strategies targeting doctors, directly interacting with key opinion leaders and doctors in the relevant treatment areas, further expanding its presence in the market, and positioning the products differently.